Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25

Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches | JCO Oncology Advances There have been significant advances in colorectal cancer (CRC) immunotherapy over the past decade, with incorporation into both the metastatic and adjuvant/neoadjuvant treatment spaces. However, ther...

Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy

The HER2 diagnostic and treatment landscape in NSCLC: Episode 1 | COR2ED This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the

HER2 in NSCLC is underrecognized & complex. Grateful to join
@cor2edmeded.bsky.social
with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks
@oncbrothers.bsky.social
for the invite! #lcsm
#oncMedEd
cor2ed.com/lung-connect...

#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇)

Full 🗣️:
⭐️ Oncbrothers.com/cabinet
⭐️ Also on the “Oncology Brothers” podcast

#OncSky #MedSky #GiOnc

I recently had the privilege of joining the @oncbrothers.bsky.social to discuss all things #PancreaticCancer, including current and emerging treatment options that are bringing hope for better outcomes for patients. Many thanks👊
oncbrothers.com/pancreatic-a...

www.cancernetwork.com/treatment-al...

Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice!

⭐️ InPerson: May 31st, 2025
⭐️ Location📍Marriott Marquis
⭐️ Time: 6:30-9:00PM
⭐️ Register bit.ly/aioasco25

#AdvInOnc25 #OncSky

#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara

Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast

#gism #CanSky #OncSky

Treatment Algorithm series: discussion on HER2+ #BreastCancer

✅ APT data/TCHP
✅ Metastatic disease
✅ Her2/ER/PR+

Full discussion:
⭐️ oncbrothers.com/her2positive...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast

#bcsm #CancerSky #OncSky

@drsarahsammons.bsky.social

What is Dr. Brian Betts most excited about for #TANDEM25? 🥁

Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...

Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement...

Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...

As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer

www.nature.com/articles/s41...

Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social

✅ Early disease
✅ ≥T2 or N+ disease
✅ Metastatic disease
✅ Low ER/PR+

Full 🗣️:
⭐️ oncbrothers.com/how-to-treat...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast

#bcsm #BreastCancer

The #GU25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GU cancers here: brnw.ch/21wQBxm

Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:

- Bladder Ca
- Prostate Ca
- RCC

*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25

#OncSky #MedSky #gusm #Oncology #Cancer #CanSky

AMPLIFY for 1L CLL now in @nejm.org

🔑 takeaways:

1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem)

2️⃣ AVO showed deeper responses but higher infection risk

3️⃣ New SoC for many

#OncSky #CanSky #HemeSky

Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social

@freddyeescorcia.bsky.social thank you for sharing this discussion.

@atoosarabiee.bsky.social this was a 4 part series (m.youtube.com/results?sp=m...) and we had a chance to have Med Onc, Hepatologist, IR, and RadOnc as part of the panel (having a transplanter/SurgOnc would have been amazing).

Intermediate HCC – the evolving role of Immunotherapy with Multimodality approaches

Nice discussion on management of intermediate risk #HCC hosted by @oncbrothers.bsky.social!

Cc: @markyarchoan.bsky.social

#liversky #oncsky

oncbrothers.com/liver-2024-4

T-DXd approved today after progression on CDK4/6 inhibitor for HR+ HER2-low and HER2-ultralow metastatic breast cancer based on results of DESTINY-Breast06. #bcsm #oncsky

T-Dxd approved as first line chemo in HR+, HER2 low or ultra low disease.

Do all patients need it first line?

Probably not. But great option for higher risk.

#bcsm #oncosky

🔥🔥🔥BREAKWATER🔥🔥🔥

BRAF V600E mut #CRC

SOC (FOLFOX) +/- encorafenib + cetuximab

EC + FOLFOX shows:

✅⬆️ORR
✅Strong suggestion of ⬆️OS

🚨EC + FOLFOX is a new SOC‼️

Pub available: idp.nature.com/authorize?re...

#GI25 @ascocancer.bsky.social

7. Role of ctDNA in CRC: #BESPOKE & @SWOG 80702 trial in Stage II/III CRC

- ctDNA+ remains prognostic for poor outcomes
- With all the data here at #GI25 on ctDNA, outside trials, how are you using this today in our clinic?

8/8

6. #BREAKWATER: Ph 3, Enco + Cetux + mFOLFOX vs SoC in BRAFV600E mCRC

- ORR 61% vs 40%
- Interim OS at 12mos 79.5% vs 66%
- Gr≥3 AEs: 37.7% vs 34.6%
- New SoC for BRAFV600E

7/8

5. #Checkmate8HW: Ph 3, dMMR/MSI-H unresectable or mCRC, Ipi (1mg/kg) + Nivo (240mg) Q3W for 4 cycles and then Nivo alone vs Nivo:

- mPFS NR for Ipi/Nivo vs 39·3 months
- ORR: 71% vs 58%
- Any grade AEs 81% from Ipi/Nivo vs 71% Nivo alone. 3 Rx related deaths.

6/8

4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year

5/8

3. PostOp chemo after PreOp mFOLFIRINOX in res panc cancer:

- PostOp chemo (multi-agent) associated with ⬆️mOS but single agent w/no improvement (selection bias)?

- Limited benefit w/ high # of pre-op chemo cycles (C8-11) or radiological response, or ypN0 disease!

4/8

2. #ESOPEC: Ph III, periop FLOT vs NeoAdj Chemoradiation in adeno esophageal Ca:

- pCR ⬆️ FLOT (17% vs 10%). Much ⬇️ pCR than original CROSS (23%)

- 3 yr OS: 57.4% vs 50.7% (mOS: 66mos vs 37mos)

3/8

1. #SCIENCE: Ph 3, resectable locally advanced ESCC, neo adj Rx: ChemoXRT vs ChemoXRT + Sintilimab (anti-PD1) vs Chemo + Sintilimab

- Significant ⬆️ in pCR w/ ChemoXRT + Sint (60%) vs ChemoXRT (47%) vs Chemo + Sint (13%)

- Awaiting longer term data before this becomes SoC

2/8

#GI25 highlights #CommunityOnc:

1. #SCIENCE: Adv Eso SCC

2. #ESOPEC publication (Eso/GEJ/Ga)

3. Chemo in resectable Panc Ca

4. #StarterNET: GEP-NET

5. #CM8HW: dMMR/MSI-H mCRC

6. #BREAKWATER: BRAFV600E mCRC

7. ctDNA: #BESPOKE + SWOG80702

#OncSky #gism @ascocancer.bsky.social

1/8

Join us for Intersections: Personalized Risk Assessment for Gastrointestinal Cancers with Mary Uan-Sian Feng, MD. Gain insights on risk scores, biomarkers for screening, and more cutting-edge updates at #GI25!